WATERTOWN, Mass., May 31 /PRNewswire/ -- V. I. Technologies, Inc. (VITEX)
(Nasdaq: VITX) announced today that James A. Moose has joined the Company as
Senior Vice President and General Manager of Plasma Operations. Mr. Moose
will have the overall responsibility for the Company's Melville, N.Y. plasma
business including manufacturing, quality, materials management and
engineering covering PLAS+(R)SD and fractionation.
Mr. Moose, age 49, joins VITEX from Gensia Sicor Pharmaceuticals, a
division of SICOR Inc. (NYSE: SCRI) of Irvine, California. As Vice President
of Operations, Mr. Moose managed strategic planning and daily operations at
the company's 200,000 square foot pharmaceutical facility for generic bulk
drugs and finished injectable dosage forms for the oncology, cardiovascular,
anti-infective and anesthesia markets. He played a key role in the company's
growth through the expansion of production and the development of appropriate
support systems. During his 6-year tenure, the company grew sales to over
$200 million.
Mr. Moose began his career at Ortho-Clinical Diagnostics, a Johnson &
Johnson company, working in plasma fractionation. In his 15 years at
Ortho-Clinical Diagnostics, Mr. Moose was promoted to positions of increasing
responsibility in the manufacturing and production of diagnostic products for
blood screening, clinical chemistry and disease prevention.
Mr. Moose received his B.S. in Biology from Lehigh University, Bethlehem,
Pennsylvania and his MBA from Rutgers University, Newark, New Jersey.
"We are fortunate to be able to attract an executive with such an
impressive pharmaceutical manufacturing background and relevant industry
knowledge," commented John Barr, President and CEO of VITEX. "Jim's extensive
experience in FDA regulated, cGMP environments and his focus on sterile
product manufacturing should be extremely beneficial to the Company. We look
forward to Jim's leadership as we develop world class manufacturing and
quality systems for PLAS+(R)SD and plasma fractions and build a culture
founded on continuous improvement."
VITEX is a leading developer and manufacturer of a broad portfolio of
blood products that utilize its patented viral inactivation technologies
designed to ensure product safety. The technologies are tailored for all
blood component applications and other blood-derived products, including
plasma, plasma derivatives, red blood cells and platelets. The first of
VITEX's virally inactivated products, PLAS+(R)SD, is the only FDA-approved
method for viral inactivation of plasma.
For further information, please visit the VITEX web site at
http://www.vitechnologies.com.
Except for the historical information contained herein, the matters
discussed are forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. These
statements involve risks and uncertainties, such as quarterly fluctuations in
operating results, the timely availability of new products, market acceptance
of the company's products, the impacts of competitive products and pricing,
government regulation of the company's products and other risks and
uncertainties set forth in the company's filings with the Securities and
Exchange Commission. These risks and uncertainties could cause actual results
to differ materially from any forward-looking statements made herein.
To receive additional information on V. I. Technologies, Inc., via fax,
at no charge, dial 1-800-PRO-INFO and enter code VITX.
SOURCE V.I. Technologies
 back to top
Related links:
http://www.vitechnologies.com
CONTACT:
John Barr, President and CEO of V.I.
Technologies, 617-726-1551, ext. 7256; or Alison Ziegler, Cecelia
Heer, or Deanne Eagle, all of The Financial Relations Board,
212-661-8030
|
